A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses
Identifieur interne : 000111 ( PascalFrancis/Checkpoint ); précédent : 000110; suivant : 000112A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses
Auteurs : KAILANG WU [États-Unis] ; LANG CHEN [États-Unis] ; GUIQING PENG [États-Unis] ; WENBO ZHOU [États-Unis] ; Christopher A. Pennell [États-Unis] ; Louis M. Mansky [États-Unis] ; Robert J. Geraghty [États-Unis] ; FANG LI [États-Unis]Source :
- Journal of virology [ 0022-538X ] ; 2011.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
How viruses evolve to select their receptor proteins for host cell entry is puzzling. We recently determined the crystal structures of NL63 coronavirus (NL63-CoV) and SARS coronavirus (SARS-CoV) receptor-binding domains (RBDs), each complexed with their common receptor, human angiotensin-converting enzyme 2 (hACE2), and proposed the existence of a virus-binding hot spot on hACE2. Here we investigated the function of this hypothetical hot spot using structure-guided biochemical and functional assays. The hot spot consists of a salt bridge surrounded by hydrophobic tunnel walls. Mutations that disturb the hot spot structure have significant effects on virus/receptor interactions, revealing critical energy contributions from the hot spot structure. The tunnel structure at the NL63-CoV/hACE2 interface is more compact than that at the SARS-CoV/hACE2 interface, and hence RBD/hACE2 binding affinities are decreased either by NL63-CoV mutations decreasing the tunnel space or by SARS-CoV mutations increasing the tunnel space. Furthermore, NL63-CoV RBD inhibits hACE2-dependent transduction by SARS-CoV spike protein, a successful application of the hot spot theory that has the potential to become a new antiviral strategy against SARS-CoV infections. These results suggest that the structural features of the hot spot on hACE2 were among the driving forces for the convergent evolution of NL63-CoV and SARS-CoV.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:11-0268018Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses</title>
<author><name sortKey="Kailang Wu" sort="Kailang Wu" uniqKey="Kailang Wu" last="Kailang Wu">KAILANG WU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang Chen" sort="Lang Chen" uniqKey="Lang Chen" last="Lang Chen">LANG CHEN</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guiqing Peng" sort="Guiqing Peng" uniqKey="Guiqing Peng" last="Guiqing Peng">GUIQING PENG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wenbo Zhou" sort="Wenbo Zhou" uniqKey="Wenbo Zhou" last="Wenbo Zhou">WENBO ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Drug Design, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pennell, Christopher A" sort="Pennell, Christopher A" uniqKey="Pennell C" first="Christopher A." last="Pennell">Christopher A. Pennell</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cancer Center, Center for Immunology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mansky, Louis M" sort="Mansky, Louis M" uniqKey="Mansky L" first="Louis M." last="Mansky">Louis M. Mansky</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute for Molecular Virology and Departments of Diagnostic and Biological Sciences and Microbiology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Geraghty, Robert J" sort="Geraghty, Robert J" uniqKey="Geraghty R" first="Robert J." last="Geraghty">Robert J. Geraghty</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Drug Design, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fang Li" sort="Fang Li" uniqKey="Fang Li" last="Fang Li">FANG LI</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0268018</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0268018 INIST</idno>
<idno type="RBID">Pascal:11-0268018</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000106</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000882</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000111</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000111</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses</title>
<author><name sortKey="Kailang Wu" sort="Kailang Wu" uniqKey="Kailang Wu" last="Kailang Wu">KAILANG WU</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lang Chen" sort="Lang Chen" uniqKey="Lang Chen" last="Lang Chen">LANG CHEN</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Guiqing Peng" sort="Guiqing Peng" uniqKey="Guiqing Peng" last="Guiqing Peng">GUIQING PENG</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wenbo Zhou" sort="Wenbo Zhou" uniqKey="Wenbo Zhou" last="Wenbo Zhou">WENBO ZHOU</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Drug Design, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pennell, Christopher A" sort="Pennell, Christopher A" uniqKey="Pennell C" first="Christopher A." last="Pennell">Christopher A. Pennell</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Cancer Center, Center for Immunology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mansky, Louis M" sort="Mansky, Louis M" uniqKey="Mansky L" first="Louis M." last="Mansky">Louis M. Mansky</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Institute for Molecular Virology and Departments of Diagnostic and Biological Sciences and Microbiology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Geraghty, Robert J" sort="Geraghty, Robert J" uniqKey="Geraghty R" first="Robert J." last="Geraghty">Robert J. Geraghty</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Center for Drug Design, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fang Li" sort="Fang Li" uniqKey="Fang Li" last="Fang Li">FANG LI</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Minneapolis, Minnesota 55455</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of virology</title>
<title level="j" type="abbreviated">J. virol.</title>
<idno type="ISSN">0022-538X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin</term>
<term>Enzyme</term>
<term>Human</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Homme</term>
<term>Angiotensine</term>
<term>Enzyme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
<term>Enzyme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">How viruses evolve to select their receptor proteins for host cell entry is puzzling. We recently determined the crystal structures of NL63 coronavirus (NL63-CoV) and SARS coronavirus (SARS-CoV) receptor-binding domains (RBDs), each complexed with their common receptor, human angiotensin-converting enzyme 2 (hACE2), and proposed the existence of a virus-binding hot spot on hACE2. Here we investigated the function of this hypothetical hot spot using structure-guided biochemical and functional assays. The hot spot consists of a salt bridge surrounded by hydrophobic tunnel walls. Mutations that disturb the hot spot structure have significant effects on virus/receptor interactions, revealing critical energy contributions from the hot spot structure. The tunnel structure at the NL63-CoV/hACE2 interface is more compact than that at the SARS-CoV/hACE2 interface, and hence RBD/hACE2 binding affinities are decreased either by NL63-CoV mutations decreasing the tunnel space or by SARS-CoV mutations increasing the tunnel space. Furthermore, NL63-CoV RBD inhibits hACE2-dependent transduction by SARS-CoV spike protein, a successful application of the hot spot theory that has the potential to become a new antiviral strategy against SARS-CoV infections. These results suggest that the structural features of the hot spot on hACE2 were among the driving forces for the convergent evolution of NL63-CoV and SARS-CoV.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-538X</s0>
</fA01>
<fA03 i2="1"><s0>J. virol.</s0>
</fA03>
<fA05><s2>85</s2>
</fA05>
<fA06><s2>11</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KAILANG WU</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LANG CHEN</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GUIQING PENG</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WENBO ZHOU</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PENNELL (Christopher A.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MANSKY (Louis M.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>GERAGHTY (Robert J.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>FANG LI</s1>
</fA11>
<fA14 i1="01"><s1>Department of Pharmacology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Center for Drug Design, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Cancer Center, Center for Immunology, University of Minnesota</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institute for Molecular Virology and Departments of Diagnostic and Biological Sciences and Microbiology, University of Minnesota Medical School</s1>
<s2>Minneapolis, Minnesota 55455</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>5331-5337</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>13592</s2>
<s5>354000192117060100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0268018</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of virology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>How viruses evolve to select their receptor proteins for host cell entry is puzzling. We recently determined the crystal structures of NL63 coronavirus (NL63-CoV) and SARS coronavirus (SARS-CoV) receptor-binding domains (RBDs), each complexed with their common receptor, human angiotensin-converting enzyme 2 (hACE2), and proposed the existence of a virus-binding hot spot on hACE2. Here we investigated the function of this hypothetical hot spot using structure-guided biochemical and functional assays. The hot spot consists of a salt bridge surrounded by hydrophobic tunnel walls. Mutations that disturb the hot spot structure have significant effects on virus/receptor interactions, revealing critical energy contributions from the hot spot structure. The tunnel structure at the NL63-CoV/hACE2 interface is more compact than that at the SARS-CoV/hACE2 interface, and hence RBD/hACE2 binding affinities are decreased either by NL63-CoV mutations decreasing the tunnel space or by SARS-CoV mutations increasing the tunnel space. Furthermore, NL63-CoV RBD inhibits hACE2-dependent transduction by SARS-CoV spike protein, a successful application of the hot spot theory that has the potential to become a new antiviral strategy against SARS-CoV infections. These results suggest that the structural features of the hot spot on hACE2 were among the driving forces for the convergent evolution of NL63-CoV and SARS-CoV.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Homme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Angiotensine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Angiotensin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Angiotensina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
<s5>06</s5>
</fC03>
<fN21><s1>178</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Kailang Wu" sort="Kailang Wu" uniqKey="Kailang Wu" last="Kailang Wu">KAILANG WU</name>
</noRegion>
<name sortKey="Fang Li" sort="Fang Li" uniqKey="Fang Li" last="Fang Li">FANG LI</name>
<name sortKey="Geraghty, Robert J" sort="Geraghty, Robert J" uniqKey="Geraghty R" first="Robert J." last="Geraghty">Robert J. Geraghty</name>
<name sortKey="Guiqing Peng" sort="Guiqing Peng" uniqKey="Guiqing Peng" last="Guiqing Peng">GUIQING PENG</name>
<name sortKey="Lang Chen" sort="Lang Chen" uniqKey="Lang Chen" last="Lang Chen">LANG CHEN</name>
<name sortKey="Mansky, Louis M" sort="Mansky, Louis M" uniqKey="Mansky L" first="Louis M." last="Mansky">Louis M. Mansky</name>
<name sortKey="Pennell, Christopher A" sort="Pennell, Christopher A" uniqKey="Pennell C" first="Christopher A." last="Pennell">Christopher A. Pennell</name>
<name sortKey="Wenbo Zhou" sort="Wenbo Zhou" uniqKey="Wenbo Zhou" last="Wenbo Zhou">WENBO ZHOU</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000111 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000111 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Checkpoint |type= RBID |clé= Pascal:11-0268018 |texte= A Virus-Binding Hot Spot on Human Angiotensin-Converting Enzyme 2 Is Critical for Binding of Two Different Coronaviruses }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |